Qureight
AI medical imaging for clinical trials, Cambridge
AI imaging CRO analysing lung and heart scans for pharma clinical trials. It raised £15m in its Series B in July 2026. It has 5 roles open, 5 of them in the UK.
Backed by Guinness Ventures, Hargreave Hale AIM VCT, Molten Ventures and XTX Ventures. Total raised ~£21.8m.
Not found on the Home Office register of licensed visa sponsors.
- 21 daystypical age of an open role
- 0roles open for more than 60 days
- 9roles taken down since we started tracking
- 0%of roles list a salary
Open roles
5 live todayOpen roles over time
Hiring momentum
Roles per weekAdded (by posting date)Closed (removed from the board)In the news (hover for headline)
Open roles by function
Open roles by team
As the company labels themIn the news
All 23 stories- LeadershipCambridge Network, 13 days agoQureight appointed imaging CRO for Phase 3 SURPASS-IPF trial as partnership with Celea Therapeutics expands
- Partnerships & dealsBusiness Weekly, 14 days agoQureight chosen by Boston-based Celea Therapeutics as imaging CRO
- ExpansionSelect Science, 1 Sept 2026Qureight expands UK footprint for AI imaging
- ExpansionManufacturing Chemist, 20 Aug 2026Qureight opens London site to expand AI-powered imaging services for clinical trials
- ExpansionNews-Medical, 19 Aug 2026Qureight expands with addition of second site, to accommodate rapid growth and ongoing development of chest Foundation Model
- ExpansionBusiness Weekly, 18 Aug 2026Qureight expands UK operations with new Holborn office